RSV vax decision deferred

NIP listing proposal for immunising infants and young children temporarily knocked back for legislative reasons A decision on the proposed NIP listing of respiratory syncytial virus (RSV) vaccine nirsevimab (Beyfortus) has been deferred, with the PBAC requiring further input from sponsor Sanofi-Aventis Australia and the Department of Health before moving forward with the proposal. The